Fri Mar 23, 2007 9:32AM EDT
LONDON/ZURICH (Reuters) - A panel of European experts said the benefits of Swiss drugmaker Roche's influenza drug Tamiflu outweighed the risks, but that it would closely monitor reports of safety concerns in Japan.
The European Medicines Agency said on Friday that "if any concerns emerge, further action will be taken."
http://www.reuters.com/article/healthNews/idUSL2348295620070323?feedType=RSS
No comments:
Post a Comment